Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 11Immunoglobulin Light-chain Amyloidosis 3Recurrence 2Neoplasms, Plasma Cell 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Rituximab 23Cyclophosphamide 15ibrutinib 14acalabrutinib 13CT-P10 10venetoclax 8Lenalidomide 8Bendamustine Hydrochloride 8fludarabine 7Cytarabine 6fludarabine phosphate 5zanubrutinib 4obinutuzumab 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4pirtobrutinib 3Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Etoposide 3palbociclib 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2brexucabtagene autoleucel 2auricularum 2Vincristine 2Stem Cell Transplantation 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Mantle-Cell × ixazomib × Clear all
NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Active not recruiting
33 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡